Amarin Corp Plcuk (AMRN) Depreciation & Amortization (CF) (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Depreciation & Amortization (CF) of $1000.0 for Q1 2026, little changed YoY from $1000.0 in Q1 2025, and little changed sequentially from $1000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $1000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $4000.0 (down 93.94% YoY), while the FY2025 annual figure was $4000.0, down 95.92% from the prior year.
- Depreciation & Amortization (CF) was little changed at $1000.0 in Q1 2026, from $1000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for AMRN reached as high as $144000.0 in Q1 2022 and fell as low as $1000.0 in Q1 2025.
- The 5-year median for Depreciation & Amortization (CF) is $32000.0 (2024), against an average of $47882.4.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) gained 3.23% — and 2025, when it sank 96.97%.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $125000.0 in 2022, then plunged by 73.6% to $33000.0 in 2023, then plunged by 75.76% to $8000.0 in 2024, then plunged by 87.5% to $1000.0 in 2025, then changed by 0.0% to $1000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1000.0, $1000.0, and $1000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 509.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.37 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |